Stock Analiz

JNJ vs ABBV stock comparison

Johnson & Johnson vs. AbbVie · data as of November 13, 2026

Johnson & Johnson (JNJ) has a market value of about $687.9B, AbbVie (ABBV) about $521.5B. Over their latest twelve months Johnson & Johnson had revenue of $99.3B and AbbVie $66.0B.

On our five checks Johnson & Johnson scores higher: 2.6 out of 5 (average) against 1.8 (weak).

By area, the stronger company is AbbVie on future growth; Johnson & Johnson on track record; Johnson & Johnson on financial health; Johnson & Johnson on shareholder returns.

Johnson & Johnson is cheaper on earnings (P/E 43.4 vs. 50.8), while AbbVie grew revenue faster over five years (5.9% vs. 2.7% a year).

Johnson & Johnson leads on 14 of the compared lines and AbbVie on 9.

Side by side

JNJABBV
Size and price
Market cap$687.9B$521.5B
Share price$285.75$295.03
Score
Overall score (of 5)2.61.8
Value00
Future growth01
Track record42
Financial health42
Shareholder returns54
Valuation
P/E (TTM)43.450.8
Forward P/E25.119.1
Price / free cash flow33.427.6
Price / sales6.97.9
EV / EBITDA26.719.8
PEG2.91—
DCF value vs. price−39%−20%
Business
Revenue$99.3B$66.0B
Net income$16.1B$10.3B
Free cash flow$20.6B$18.9B
Net margin16.2%15.7%
Gross margin (5-yr avg.)69.1%68.3%
ROIC (5-yr avg.)16.6%15.3%
Growth
Revenue growth (1 yr)6.0%8.6%
Revenue growth (5 yrs, per year)2.7%5.9%
EPS growth (5 yrs, per year)14.9%-2.8%
Balance sheet and payouts
Net cash (cash minus debt)-$27.4B-$61.5B
Dividend yield1.88%2.35%
Shareholder yield2.8%2.5%
Analysts
Upside to average target−2%+6%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: JNJ TTM to September 27, 2026, ABBV TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Johnson & Johnson or AbbVie?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Johnson & Johnson scores 2.6 out of 5 and AbbVie 1.8; the table shows where each one is stronger.

Is Johnson & Johnson cheaper than AbbVie?

On trailing earnings, Johnson & Johnson trades at a P/E of 43.4 and AbbVie at 50.8, so Johnson & Johnson is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Johnson & Johnson or AbbVie?

Over five years AbbVie grew revenue about 5.9% a year and Johnson & Johnson about 2.7% a year.

Which pays a higher dividend?

Johnson & Johnson yields 1.88% and AbbVie 2.35%.

Full Johnson & Johnson analysis → Full AbbVie analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.